Glycoprotein IIb/IIIa Receptor Blockade Improves Outcomes in Diabetic Patients Presenting With Unstable Angina/Non–ST-Elevation Myocardial Infarction: Results From the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study
暂无分享,去创建一个
S. Snapinn | P. Théroux | E. Barr | C. Pharand | F. Sax | J. Alexander | P. Théroux | Asma F. Ghannam
[1] Deepak L. Bhatt,et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. , 2000, Journal of the American College of Cardiology.
[2] Teven,et al. MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .
[3] Deepak L. Bhatt,et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. , 1999, Circulation.
[4] E. Mahmud,et al. Will blocking the platelet save the diabetic? , 1999, Circulation.
[5] J. López-Sendón,et al. Prognosis of medically stabilized unstable angina pectoris with a negative exercise test. , 1998, The American journal of cardiology.
[6] David P Miller,et al. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. , 1998, Circulation.
[7] C. Bauters,et al. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis. , 1998, Circulation.
[8] Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. , 1998, The New England journal of medicine.
[9] G. Davı̀,et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. , 1997, Circulation.
[10] Nicole E. Jelesoff,et al. Outcomes of Diabetic Patients Following Acute Myocardial Infarction: A Review of the Major Thrombolytic Trials , 1997, Journal of cardiovascular risk.
[11] J. Chesebro,et al. Mechanisms Determining Course and Outcome of Diabetic Patients Who Have Had Acute Myocardial Infarction , 1997, Annals of Internal Medicine.
[12] R. Califf,et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. , 1997, Journal of the American College of Cardiology.
[13] R. Califf,et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. , 1996, Journal of the American College of Cardiology.
[14] D. Faxon,et al. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. , 1996, Circulation.
[15] H. Oskarsson,et al. Platelets from patients with diabetes mellitus have impaired ability to mediate vasodilation. , 1996, Journal of the American College of Cardiology.
[16] C. White,et al. Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients. , 1995, Circulation.
[17] W. Weintraub,et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. , 1995, Circulation.
[18] S. Shukla,et al. Hypersensitivity of diabetic human platelets to platelet activating factor. , 1992, Thrombosis research.
[19] R Roberts,et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.
[20] D L McGee,et al. Diabetes and Cardiovascular Risk Factors: The Framingham Study , 1979, Circulation.
[21] D.,et al. Regression Models and Life-Tables , 2022 .